← Leaderboards
Virginia Athena Triant
Massachusetts General Hospital
$9,524,641
Attributed
$11,250,932
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,250,932 · 6
By mechanism
R01$9,484,319 · 3
R56$820,763 · 1
K01$686,808 · 1
R21$259,042 · 1
Top collaborators
- Ralph B D'Agostino4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Guillermo J. Tearney$42,608,505
- Raymond T Chung$38,306,004
- Steven Kyle Grinspoon$75,757,679
- Ahmed A Tawakol$9,912,063
- Brett E Bouma$16,028,207
Others in their field
Top investigators on “Risk Factors”
- Jeffrey P Krischer · University Of South Florida$393,499,152
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard Webby · St. Jude Children'S Research Hospital$180,330,417
- John M Lachin · George Washington University$139,236,598
Research focus
Risk FactorsCardiovascular DiseasesCohortCardiovascular Risk FactorCaringInflammationCardiovascular Disorder RiskHiv InfectionsPrevention StrategyAntiretroviral TherapyClinical CareAcute Myocardial InfarctionAlgorithmsPerformanceResearch DesignAgingInflammatoryCardiovascular Disorder PreventionEventRisk ReductionMultidisciplinaryChronicInnovationProspective
Grant awards (20)
Enhancing cardiovascular risk prediction in HIV using novel factors in the REPRIEVE trial$726,319
R01 · FY2025 · HL · contact PI
Enhancing cardiovascular risk prediction in HIV using novel factors in the REPRIEVE trial$773,364
R01 · FY2024 · HL · contact PI
Cardiovascular Risk Reduction in an Aging HIV-Infected Population: The Impact of HCV Co-Infection$800,488
R01 · FY2023 · AG · contact PI
Cardiovascular Risk Reduction in an Aging HIV-Infected Population: The Impact of HCV Co-Infection$817,262
R01 · FY2022 · AG · contact PI
Enhancing cardiovascular risk estimation in individuals aging with HIV/HCV co-infection$418,321
R01 · FY2022 · AG · contact PI
Cardiovascular Risk Reduction in an Aging HIV-Infected Population: The Impact of HCV Co-Infection$815,255
R01 · FY2021 · AG · contact PI
Optimizing Cardiovascular Risk Prediction in HIV$852,205
R01 · FY2020 · HL · contact PI
Cardiovascular Risk Reduction in an Aging HIV-Infected Population: The Impact of HCV Co-Infection$823,218
R01 · FY2020 · AG · contact PI
Cardiovascular Risk Reduction in an Aging HIV-Infected Population: The Impact of HCV Co-Infection$857,509
R01 · FY2019 · AG · contact PI
Optimizing Cardiovascular Risk Prediction in HIV$851,435
R01 · FY2019 · HL · contact PI
Optimizing Cardiovascular Risk Prediction in HIV$855,247
R01 · FY2018 · HL · contact PI
Optimizing Cardiovascular Risk Prediction in HIV$893,696
R01 · FY2017 · HL · contact PI
Statin Use and Efficacy Among HIV-Infected Patients by Cholesterol Risk Category$128,542
R21 · FY2015 · HL · contact PI
Evaluation and development of cardiovascular risk prediction algorithms in HIV$820,763
R56 · FY2014 · HL · contact PI
Statin Use and Efficacy Among HIV-Infected Patients by Cholesterol Risk Category$130,500
R21 · FY2014 · HL · contact PI
Incidence and Predictors of Myocardial Infarction Among HIV-Infected Patients$137,922
K01 · FY2012 · AI · contact PI
Incidence and Predictors of Myocardial Infarction Among HIV-Infected Patients$137,958
K01 · FY2011 · AI · contact PI
Incidence and Predictors of Myocardial Infarction Among HIV-Infected Patients$137,796
K01 · FY2010 · AI · contact PI
Incidence and Predictors of Myocardial Infarction Among HIV-Infected Patients$136,806
K01 · FY2009 · AI · contact PI
Incidence and Predictors of Myocardial Infarction Among HIV-Infected Patients$136,326
K01 · FY2008 · AI · contact PI